How Siokas was paid
$3.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Other | Total |
|---|---|---|---|---|---|
| Grigorios SiokasChairman and Chief Executive Officer | $1,080,000 | $1,800,000 | $672,300 | — | $3,552,300 |
| Georgios TerzisChief Financial Officer | $148,235 | $200,000 | $244,020 | — | $592,255 |
| Nikolaos BardakisChief Operating Officer | $23,949 | — | $15,426 | — | $39,375 |
| Suhel BhutawalaCommercial Director, Decahedron Ltd. | $66,405 | — | $7,470 | $10,000 | $83,875 |
What changed and why
- $3.6M$3,552,300 was the CEO’s 2025 total compensation, versus $2,904,100 in 2024.
- $1.8M$1,800,000 bonus and $672,300 stock awards comprised the CEO’s 2025 incentive compensation.
- 2,350,000 restricted stock awards were granted under the 2024 Plan on December 30, 2025.
- 6,000,000 shares were reserved under the 2025 Omnibus Equity Incentive Plan.
- No financial performance measures were used to link 2025 NEO compensation.
- $19.1M$19,144,998 was the company’s 2025 net loss.
Other Cosmos Health proxy statements
- 2025 proxy statement
Grigorios Siokas paid $2.9M (+1% on the year).
Filed Aug 22, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.